NCT01137695View on ClinicalTrials.gov

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

April 30, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Pramlintide

120 mcg SQ three times daily for 6 months.

DRUG

Pramlintide

360 mcg SQ three times daily for 6 months

DRUG

Pramlintide

120 mcg SQ three times daily for 6 months

DRUG

Pramlintide

360 mcg SQ three times daily for 6 months

Trial Locations (3)

10301

University Physicians Group, Staten Island

19047

St. Mary Medical Center, Langhorne

07834

North Jersey Endocrine Consultants, Denville

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

Cheryl Rosenfeld, DO

OTHER